Abstract
Marine actinomycetes were the main origin of marine natural products in the past 40 years. This review was to present the sources, structures and antimicrobial activities of 313 new natural products from marine actinomycetes reported from 1976 to 2019.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Marine actinomycetes were the major resource of marine natural products owing to their chemical structures and diverse bioactivities. According to a statistic analysis of marine microbial natural products from 2010 to 2013, marine-derived actinomycetes accounted for 28% (= 253/895) of new marine natural products isolated from microbial origin (Zhao et al. 2013). This review covered the sources, structures and antimicrobial activities of 313 compounds derived from marine actinomycetes reported from 1976 to 2019. These new antimicrobial compounds have diverse chemical structures including polyketides, nitrogen-containing compounds, sterols and terpenoids. Majority of these compounds were antibacterial natural products, which consisted of 87% of the new marine natural products from marine-derived actinomycetes.
Antimicrobial compounds from Streptomyces species
Antimicrobial compounds from Streptomyces sp. associated with sponges
Urauchimycins A and B (1 and 2) (Fig. 1) were isolated from Streptomyces sp. Ni-80. Compounds 1 and 2 exhibited antifungal activity against Candida albicans at 10 μg/mL (Imamura et al. 1993). Eight new antibacterial streptophenazines A–H (3‒10) were obtained from Streptomyces sp. HB202 (Mitova et al. 2008). These compounds showed broad spectrum of inibitory activity against bacterial strains with MIC values ranging from 15.6 to 62.5 µg/mL (Mitova et al. 2008). Mayamycin (11) exhibited antibacterial activity with MIC values ranging from 2.5 to 8.4 µg/mL (Schneemann et al. 2010). Streptophenazine K (12) was isolated from Streptomyces HB202, which showed antibacterial activity against B. subtilis and S. epidermidis with MIC values of 21.6 and 14.5 μM, respectively (Kunz et al. 2014). Streptomyces sp. BCC45596 yielded urdamycinone E (13), urdamycinone G (14), and dehydroxyaquayamycin (15), which were active against M. tuberculosis with MIC values of 3.13, 12.50 and 6.25 μg/mL, respectively (Supong et al. 2012). Jiao et al. isolated four new compounds from Streptomyces sp. LHW52447, namely actinomycins D1 − D4 (16–19), which displayed inhibitory activity against S. aureus (MRSA) with MIC values ranging from 0.125 to 1.0 μg/mL (Jiao et al. 2018).
Antimicrobial compounds from Streptomyces sp. associated with corals
Four nahuoic acids B–E (20–23) were isolated from Streptomyces sp. SCSGAA 0027, which exhibited weak antibiofilm activity against Shewanella onedensis MR-1 biofilm (Nong et al. 2016). Streptomyces sp. M-207 produced lobophorin K (24), which inhibited S. aureus EPI167 (MRSA) with an MIC90 value in the range of 40−80 µg/mL (Braña et al. 2017a). Anthracimycin B (25) was obtained from a culture of Streptomyces cyaneofuscatus M-169, which displayed antimicrobial activity against S. aureus MRSA (MB5393), S. aureus MSSA (ATCC 29213), E. faecium VANS (CL144754) and E. faecalis VANS (CL144492) with MICs below the lowest concentration tested at 0.03 µg/mL and inhibited M. tuberculosis (H37Ra) with an MIC value of 1−2 µg/mL (Rodríguez et al. 2018). Isotirandamycin B (26) was isolated from a culture of Streptomyces sp. SCSIO 41399, which displayed antimicrobial activity against Streptococcus agalactiae with an MIC value of 11.5 μM (Cong et al. 2019).
Antimicrobial compounds from Streptomyces sp. associated with other marine animals
Streptomyces hygroscopicus yielded salinamides A (27) and B (28). Both compounds were active against S. pneumoniae with an equal MIC value of 4 μg/mL. Both compounds were also active against S. pyrogenes with MIC values of 4 and 2 μg/mL, respectively (Trischman et al. 1994). Streptomyces sp. 1053U.I.1a.3b produced lobophorin I (29), which exhibited inhibitory activity against M. tuberculosis and B. subtilis with MIC values of 2.6 and 10.6 μM, respectively (Lin et al. 2014). Salinamide F (30) (Fig. 2) obtained from Streptomyces sp. CNB091, had a broad spectrum of antibacterial activity (Hassan et al. 2015). Streptoseomycin (31) was isolated from Streptomyces seoulensis A01, which exhibited inhibitory activityagainst H. pylori, Lactobacillus acidophilus, Bifidobacterium bifidum, Eubacterium brachy, Propionibacterium acnes, S. aureus, Micrococcus luteus and B. subtilis with MIC values ranging from 2 to 64 μg/mL (Zhang et al. 2018a).
Antimicrobial compounds from Streptomyces sp. associated with marine algae
Bisanthraquinone derivatives A−C (32‒34), were isolated from Streptomyces sp. N1-78-1, which displayed antimicrobial activity against MRSA with IC50 values of 0.15, 0.36 and 31 μM, respectively (Socha et al. 2006). 2-Hydroxy-5-((6-hydroxy-4-oxo-4H-pyran-2-yl) methyl)-2-propylchroman-4-one (35) was obtained from Streptomyces sp. WR1L1S8, which showed antibacterial activity against E. coli ATCC 25922 and MRSA ATCC 43300 with MIC values of 16 and 2 μM, respectively (Djinni et al. 2013). Braña et al. isolated desertomycin G (36) from Streptomyces althioticus MSM3, which exhibited inhibitory activity against a wide spectrum of bacterial strains, with MIC values ranging from 4 to 64 µg/mL (Braña et al. 2019).
Antimicrobial compounds from Streptomyces sp. associated with mangrove
Divergolides A–D (37–40), were isolated from a culture of Streptomyces sp. HKI0576, which displayed antimicrobial activity against B. subtilis, Mycobacterium vaccae and MRSA with inhibition zone diameters of 10−20 mm (Ding et al. 2011a). Xiamycin B (41), indosespene (42), and sespenine (43) were obtained from Streptomyces sp. HKI0595, which exhibited antibacterial activity against MRSA (Ding et al. 2011b). Kandenols A–E (44‒48) were isolated from Streptomyces sp. HKI0595, which showed weak antimicrobial activity against B. subtilis ATCC 6633 and Mycobacterium vaccae IMET 10,670 (Ding et al. 2012). Antimycin B2 (49) was discovered from S. lusitanus XM52, which displayed antibacterial activity against S. aureus and L. hongkongensis with MIC values of 32 and 8 μg/mL, respectively (Han et al. 2012).
Antimicrobial compounds from Streptomyces sp. associated with other plants
Streptomyces sp. MA-12 yielded 7,3′-di-(γ, γ-dimethylallyloxy)-5-hydroxy-4′-methoxyflavone (50). Compound 50 was active against C. musae, G. zeae (Schweinitz) Petch, and P. citrinum at 0.25 mM with inhibition zone diameters of 12.7, 13.00 and 12.17 mm, respectively (Ding et al. 2013). Juanlimycin A (51) was isolated from a culture of Streptomyces sp. LC6, which showed moderate inhibition on the secretion of Salmonella Pathogenicity Island-1 effectors, SipA/B/C/D (Zhang et al. 2014).
Antimicrobial compounds from Streptomyces sp. from marine sediments
Aplasmomycins A−C (52‒54) were isolated from S. griseus SS-20, which inhibited the growth of Gram-positive bacteria (Okami et al. 1976; Sato et al. 1978). Istamycins A and B (55 and 56) were purified from S. tenjimariensis SS-939, which showed inhibition against Gram-positive and Gram-negative bacteria (Okami et al. 1979). Phenazine alkaloid (57) was obtained from a culture of Streptomyces sp. CNB-253, which displayed antimicrobial activity against Hemophilus influenza and Clostridium perfringens with MIC values of 1 and 4 μg/mL, respectively (Pathirana et al. 1992). Wailupemycin A (58) (Fig. 3) and 3-epideoxyenterocin (59) were isolated from Streptomyces sp. BD-26 T(20) (Sitachitta et al. 1996). Compound 58 showed antibacterial activity against S. aureus with an inhibition zone diameter of 18 mm at 1 mg/6 mm disk. Compound 59 showed antibacterial activity against E. coli with an inhibition zone diameter of 15 mm at 0.1 mg/6 mm disk. δ-Indomycinone (60) was obtained from Streptomyces sp. B 8300, which showed antibacterial activity against B. subtilis with an MIC value of 100 µg/mL (Biabani et al. 1997). Streptomyces sp. CNB-689 produced actinoflavoside (61), which exhibited wide antibacterial activity against S. pneumonia, S. pyrogenes, S. aureus and M. luteusat with an equal MIC value of 64 µg/mL (Jiang et al. 1997). Dimethyl 5, 10-dihydrophenazine-l,6-dicarboxylate (5, 10-Dihydrophencomycin methyl ester) (62) was isolated from Streptomyces sp. B 8251, which displayed weak antimicrobial activity against E. coli and B. subtilis (Pusecker et al. 1997). Lysophosphatidyl inositols A and B (63 and 64) were isolated from Streptomyces sp. M428, and both compounds showed antifungal activities against C. albican with MIC values of 5.0 and 2.5 μg/mL, respectively (Cho et al. 1999). Lornemide A (65) was discovered from Streptomyces sp. MSTMA190, which demonstrated inhibitory activity against B. subtilitis with a LD99 value of 50 μg/mL (Capon et al. 2000). 2-Amino-9,13-dimethyl heptadecanoic acid (66) was produced by Streptomyces sp. 1010, which showed inhibitory activity against M. luteus and B. subtilis with MIC values of 15 and 50 μg/mL, respectively (Ivanova et al. 2001). A study of Streptomyces sp. B7064 led to the identification of chalcomycin B (67), which displayed antibacterial activity against S. aureus, E. coli and B. subtilis with inhibition zone diameters of 23, 28, and 21 mm at 10 μg/disk, respectively (Asolkar et al. 2002). Bonactin (68) was isolated from Streptomyces sp. BD21-2 and was active against S. aureus, B. megaterium and S. cerevisiae with the inhibition zone diameters of 7.0, 8.0 and 7.5 mm at 1 mg/mL, respectively (Schumacher et al. 2003). Lajollamycin (69) was discovered from S. nodosus NPS007994, which displayed antibacterial activity against S. pneumonia and S. aureus with MIC values of 1.5 and 5 µg/mL, respectively (Manam et al. 2005). Daryamides A and B (70 and 71) was obtained from Streptomyces sp. CNQ-085, which exhibited antifungal activity against C. albicans with MIC values of 62.5 and 125 μg/mL, respectively (Asolkar et al. 2006). 5,7-Dihydroxy-5,6,7,8-tetrahydroazocin-2(1H)-one (72) obtained from Streptomyces sp. QD518 showed inhibitory activity against S. aureus at 40 μg/disc with an inhibition zone diameter of 11 mm (Wu et al. 2006). Streptomyces sp. B8000 yielded 8-hydroxy-3-methoxy-1-propylanthraquinone (73), which was active against S. aureus and Streptomyces viridochromogenes at 40 μg/disc with inhibition zone diameters of 14 and 12 mm, respectively (Poumale et al. 2006). Marinopyrroles A (74) and B (75) were isolated from a culture of Streptomyces sp. CNQ-418, which demonstrated antimicrobial activity against MRSA with MICs of 0.61 and 1.10 μM, respectively (Hughes et al. 2008). Marinopyrrole C (76) displayed antimicrobial activity against MRSA with an MIC value less than 1 µg/mL (Hughes et al. 2010). Streptomyces sp. MS239 produced 77, which showed weak antibacterial activity against B. subtilis ATCC6633 (Motohashi et al. 2008). Essramycin (78) was obtained from Streptomyces sp. Merv8102, which displayed antibacterial activity against E. coli (ATCC 10536), P.aeruginosa (ATCC 10145), B. subtilis (ATCC6051), S. aureus (ATCC 6538), and M. luteus (ATCC 9341) with the MIC values of 8.0, 3.5, 1.0, 1.0 and 1.5 μg/mL, respectively (El-Gendy et al. 2008). Tirandamycin C (79) was isolated from a culture of Streptomyces sp. 307–9, which demonstrated antimicrobial activity against vancomycin-resistant E. faecalis with an MIC value of 110 μM (Carlson et al. 2009). 8-Deoxyheronamide C (80) was isolated from Streptomyces sp. CMB-M0406, which exhibited inhibitory activity against wild-type fission yeast with an MIC value of 5.8 μM (Sugiyama et al. 2014). Heronapyrroles A−C (81‒83) (Fig. 4) were isolated from Streptomyces sp. CMB-M0423, which inhibited the growth of Gram-positive bacteria with MIC values ranging from 0.6 to 6.5 μM (Raju et al. 2010). Antimycins A19 and A20 (84 and 85) were discovered from S. antibioticus H74-18, which displayed antifungal activity against C. albicans with MIC values of 5 and 10 μg/mL, respectively (Xu et al. 2011). Fijimycins A‒C (86‒88) were obtained from Streptomyces sp. CNS-575, which inhibited the growth of MRSA (ATCC33591, Sanger 252, UAMS1182) with MIC values ranging from 4 to 16 μg/mL (Sun et al. 2011). Glucopiericidin C (89) isolated from Streptomyces sp. B8112 was active against Mucor miehei (Shaaban et al. 2011). Lobophorin F (90) was produced by Streptomyces sp. SCSIO 01127, which demonstrated inhibitory activity against S. aureus ATCC 29213 and E. faecalis ATCC 29212 with an equal MIC value of 8 μg/mL (Niu et al. 2011). Ansalactams B−D (91‒93) were purified from Streptomyces sp. CNH-189, which exhibited inhibitory activities against MRSA with MIC values of 31.2, 31.2 and 62.5 μg/mL, respectively (Wilson et al. 2011). Three compounds meroindenon (94), merochlorins E (95) and F (96) were produced by Streptomyces sp. CNH-189. Compound 94 displayed antibacterial activity against B. subtilis, K. rhizophila and S. aureus with MIC values of 16, 64 and 128 μg/mL, respectively. Compounds 95 and 96 displayed antibacterial activities against B. subtilis, K. rhizophila and S. aureus with MIC values in the range of 1−2 μg/mL (Ryu et al. 2019). Coumpounds 97 and 98 identified from Streptomyces sp. 211,726 were active against C. albicans with MIC values of 2.34 and 12.50 μg/mL, respectively (Yuan et al. 2011). Heronamycin A (99) was produced by Streptomyces sp. CMB-M0392, which displayed inhibition against B. subtilis ATCC6052 and ATCC6633 with MIC values of 8 and 14 μg/mL, respectively (Raju et al. 2012). Bahamaolide A (100) was produced by Streptomyces sp. CNQ343, which showed inhibition against C. albicans and various pathogenic fungi (Kim et al. 2012). Geranylphenazinediol (101) was isolated from Streptomyces sp. LB173, which exhibited weak antibacterial activity (Ohlendorf et al. 2012). Dixiamycins A (102) and B (103), oxiamycin (104) and chloroxiamycin (105) were purified from Streptomyces sp. SCSIO 02999, which demonstrated inhibitory activity against E. coli ATCC 25922 with MIC values of 8, 8, 16 and 4 μg/mL, respectively (Zhang et al. 2012). Compounds 102‒105 also exhibited inhibitory activity against S. aureus ATCC29 213 with MIC values of 8, 16, 16 and 8 μg/mL, respectively. Compounds 102, 103 and 105 displayed inhibitory activity against B. subtilis SCSIO BS01 with MIC values of 64, 128 and 64 μg/mL, respectively. Compounds 102 and 103 showed inhibitory activity against B. thuringiensis SCSIO BT01 with MIC values of 64 and 64 μg/mL, respectively. Streptosetin A (106) was obtained from Streptomyces sp. CP13-10, and it displayed antifungal activity against yeast Sir2p with an MIC value of 2.5 mM (Amagata et al. 2012). Streptomyces sp. RJA2961 was reported to produce novobiocin (107) (Fig. 5), desmethylnovobiocin (108) and 5-hydroxynovobiocin (109), which displayed antibacterial activity against MRSA (ATCC 33,591) with MIC values of 0.25, 16 and 8 μg/mL, respectively (Dalisay et al. 2013). Iso-16-deethylindanomycin (110), 16-deethylindanomycin methyl ester (111) and iso-16-deethylindanomycin methyl ester (112) were isolated from a culture of S. antibioticus PTZ0016, which showed antimicrobial activity against S. aureus ATCC6538 with MIC values of 6.0, 6.0 and 8.0 μg/mL, respectively (Lian et al. 2013). Three compounds marfuraquinocins A (113), C and D (114 and 115) were produced by S. niveus SCSIO 3406, and they displayed antibacterial activities against S. aureus ATCC 29,213 with an equal MIC value of 8 μg/mL. Compounds 114 and 115 showed antibacterial activities against methicillin-resistant Staphylococcus epidermidis shhs-E1 with an equal MIC value of 8 μg/mL (Song et al. 2013). Streptomyces sp. MS100061 yielded lobophorin G1 (116), which inhibited the growth of B. subtilis and M. tuberculosis H37Rv with MIC values of 3.1 and 32 μg/mL, respectively (Chen et al. 2013). Napyradiomycins A and B (117 and 118) were produced by Streptomyces sp. CNQ-329, which possessed inhibitory activity against MRSA with MIC values of 16 and 64 μg/mL, respectively (Cheng et al. 2013). Designated 4-dehydro-4a-dechlorona pyradiomycin A1 (119), 3-dechloro-3-bromonapyradiomycin A1 (120), and 3-chloro-6,8-dihydroxy-8-α-lapachone (121) from Streptomyces sp. SCSIO 10,428 exhibited antibacterial activity against B. thuringensis SCSIO BT01 with MIC values of 8, 1 and 16 μg/mL, respectively. They exhibited antibacterial activity against B. subtilis SCSIOBS01 with MIC values of 4, 1 and 8 μg/mL, respectively (Wu et al. 2013a). Compounds 119 and 120 showed antibacterial activity against S. aureus ATCC 29,213 with MIC values of 4.0 and 0.5 μg/mL, respectively. Streptomyces sp. CNH365 afforded anthracimycin (122), which exhibited antibacterial activity against B. anthracis UM23C1-1, S. aureus ATCC, E. faecalis ATCC 29,212, S. pneumoniae ATCC 51,916 and H. influenzae ATCC 31,517 with MIC values of 0.03125, 0.0625, 0.125, 0.25 and 4 μg/mL, respectively (Jang et al. 2013). 11′,12′-Dehydroelaiophylin (123) and 11,11′-O-dimethyl-14′-deethyl-14′-methylelaiophylin (124) were isolated from Streptomyces sp. 7–145, which displayed good inhibitory activity against MRSA and vancomycin-resistant enterococci pathogens (Wu et al. 2013b). Two new compounds ohmyungsamycins A (125) and B (126) were isolated from Streptomyces sp. SNJ042. Compound 125 exhibited inhibitory activity against B. subtilis ATCC6633, K. rhizophila NBRC12708 and P. hauseri NBRC3851 with MIC values of 4.28, 1.07 and 2.14 μM, respectively, while compound 126 was active against K. rhizophila NBRC12708 with an MIC value of 8.5 μM (Um et al. 2013). Lobophorin H (127) was discovered from Streptomyces sp. 12A35, which displayed inhibitory activity against S. aureus ATCC29213 and B. subtilis CMCC63501 with MIC values of 50 and 1.57 μg/mL, respectively (Pan et al. 2013). Mollemycin A (128) was identified from Streptomyces sp. CMBM0244 and it was active against S. aureus ATCC 25293 and ATCC 9144, S. epidermidis ATCC 12228, B. subtilis ATCC 6051 and ATCC 6633, E. coli ATCC 25922, P. aeruginosa ATCC 27853 and Mycobacterium bovis (BCG) with MIC values of 50, 10, 50, 10, 10, 10, 50 and 3200 nM, respectively (Raju et al. 2014). Marformycins A−E (129‒133) exhibited inhibitory activities against M. luteus with MIC values of 0.25, 4.0, 0.25, 0.063 and 4.00 μg/mL, respectively (Zhou et al. 2014). Desotamide B (134) was obtained from a culture of S. scopuliridis SCSIO ZJ46, which demonstrated antimicrobial activity against S. aureus ATCC29213, S. pnuemoniae NCTC 7466 and MRSA with MIC values of 16.0, 12.5 and 32.0 μg/mL, respectively (Song et al. 2014). Glycosylated macrolactins A1 (135) and B1 (136) were isolated from Streptomyces sp. 06CH80, which displayed antibacterial activities against B. subtilis, E. coli, P. aeruginosa, S. aureus and S. cerevisiae with MIC values in the range of 0.027 to 0.22 μM/mL (Mondol and Shin 2014). Buanmycin (137) was isolated from Streptomyces sp. SNR69, and compound 137 exhibited antibacterial activity against five bacterial strains with MIC values ranging from 0.7 to 21.1 μg/mL (Moon et al. 2015). Chemical investigation of a culture extract of Streptomyces sp. CMB-M0150 led to the discovery of aranciamycins I (138) (Fig. 6) and J (139). 138 and 139 showed inhibitory activity against M. tuberculosissurrogate with MIC values in the range of 0.7 to 1.7 μM, respectively (Khalil et al. 2015). A fermentation broth of Streptomyces sp. SNM5 yielded mohangamides A (140) and B (141), which exhibited inhibitory activity against C. albicans ICL with IC50 values of 4.4 and 20.5 μM, respectively (Bae et al. 2015a). Hormaomycins B (142) and C (143) from Streptomyces sp. SNM5 displayed broad antibacterial activities with MIC values ranging from 0.23 to 114 µM (Bae et al. 2015b). Streptomyces zhaozhouensis CA-185989 yielded isoikarugamycin (144), 28-N-methylikarugamycin (145), and 30-oxo-28-N-methylikarugamycin (146). 144– 146 were active against MRSA with MIC values of 1–4, 1–4, 32–64 μg/mL, respectively. Compound 144 was active against C. albicans and A. fumigatus with MIC values of 2–4 and 4–8 μg/mL, respectively, and 145 was active against C. albicans and A. fumigatus with MIC values of 4 and 4–8 μg/mL, respectively (Lacret et al. 2015). S. rochei 06CM016 yielded compounds 147 and 148. 147 showed antimicrobial activity against E. coli O157:H7 RSKK 234, MRSA DSM 11729 and C. albicans DSM 5817 with MIC values of 16, 8 and 4 μg/mL, respectively (Aksoy et al. 2016). 148 exhibited antimicrobial activity against E. coli O157:H7 RSKK 234, MRSA DSM 11729 and C. albicans DSM 5817 with MIC values of 16, 16 and 8 μg/mL, respectively (Aksoy et al. 2016). N-acetyl-N-demethylmayamycin (149) was obtained from Streptomyces sp. 182SMLY, which was active against MRSA with an MIC of 20.0 μM (Liang et al. 2016). Neo-actinomycins A (150) and B (151) were discovered from Streptomyces sp. IMB094, which displayed antibacterial activity against MRSA and vancomycin-resistant Enterococci with MIC values in the range of 16 to 64 μg/mL (Wang et al. 2017). Strepchazolin A (152) was obtained from Streptomyces chartreusis NA02069, which showed antibacterial activity against B. subtilis with an MIC value of 64 μM (Yang et al. 2017). Jiang et al. isolated four new naphthoquinone derivatives from Streptomyces sp. XMA39, namely strepoxepinmycins A–D (153–156), which displayed inhibitory activity against a wide spectrum of strains with MIC values ranging from 6.0 to 10.0 μg/mL (Jiang et al. 2018). Bagremycins F (157) and G (158) were obtained from Streptomyces sp. ZZ745 and they showed inhibitory activities against E. coli with MIC values of 41.8 and 67.1 µM, respectively (Zhang et al. 2018b). Streptomyces Pratensis NA-ZhouS1 yielded stremycins A (159) and B (160). 159 and 160 were active against P. aeruginosa, MRSA, K. pneumonia and E. coli with the same MIC value of 16 µg/mL. Both were also active against B. subtilis with MIC values from 8 to 16 µg/mL (Akhter et al. 2018). Tunicamycin E (161) was obtained from Streptomyces xinghaiensis SCSIO S15077, which exhibited inhibitory activity against B. thuringiensis BT01, B. thuringiensis, C. albicans (ATCC 96901) and C. albicans CMCC (F) 98001 with MIC values of 2.0, 0.5, 32 and 8 μg/mL, respectively (Zhang et al. 2018c). A fermentation broth of Streptomyces sp. ZZ446 yielded a new compound maculosin-O-α-L-rhamnopyranoside (162), which showed antimicrobial activity against MRSA, E. coli and C. albicans with MIC values of 37.0, 28.0 and 26.0 µg/mL, respectively (Chen et al. 2018a). Niphimycins C−E (163−165) and 17-O-methylniphimycin (166) were isolated from a culture of Streptomyces sp. IMB7-145, which displayed antimicrobial activity against C. albican with MIC values of 8−32 μg/mL (Hu et al. 2018). Compound 163 showed anti-bacterial activity against MRSE, MRSA and M. tuberculosis with MIC values ranging from 4 to 64 μg/mL. Streptomyces mutabilis sp. MII yielded N-acetylborrelidin B (167), which was active against B. subtilis, B. cereus and S. aureus with inhibition zone diameters of 8−11 mm. Compound 167 was also active against S. warneri with an inhibition zone diameter of 18 mm (Hamed et al. 2018a). Nivelactam B (168) (Fig. 7), a new biphenyl derivative, was obtained from S. varsoviensis HF-11225, which exhibited inhibitory activity against Sclerotinia sclerotiorum with an inhibition zone diameter of 9 mm at 100 μg per 7 mm paper disks (Chen et al. 2018b). Nosiheptide (169), griseoviridin (170) and etamycin (171) were produced by Streptomyces sp. OPMA 1245. Compound 169 displayed antibacterial activity against M. avium JCM15430, M. intracellulare JCM6384 and M. bovis BCG Pasteur with MIC values of 0.024, 0.024 and 0.012 µg/mL, respectively. Compound 170 showed antibacterial activity against M. avium JCM15430, M. intracellulare JCM6384 and M. bovis BCG Pasteur with MIC values of 1.56, 1.56 and 6.25 µg/mL, respectively. Compound 171 was active against M. avium JCM15430, M. intracellulare JCM6384 and M. bovis BCG Pasteur with MIC values of 0.097, 0.190 and 0.780 µg/mL, respectively (Hosoda et al. 2019). Streptomyces sp. ZZ820 yielded diterpenoids 18-acetyl-cyclooctatin (172), 5,18-dedihydroxy-cyclooctatin (173) and 5-dehydroxy-cyclooctatin (174), which inhibited the growth of MRSA and E. coli with MIC values ranging from 24.11 to 55.12 μM (Yi et al. 2019). Streptomyces sp. G212 produced 2,4-dichlorophenyl 2,4-dichloro benzoate (175) and 4,5-dihydroxy-7-methylphthalide (176). Compound 175 exhibited inhibitory activity against C. albicans with an MIC value of 64 μg/mL, and compound 176 inhibited E. faecalis with the same MIC value of 64 μg/mL (Cao et al. 2019). Streptoglutarimides A–J (177–186) were obtained from Streptomyces sp. ZZ741. 177–186 showed antifungal activity against C. albicans with MIC values in the range of 8−20 μg/mL. They showed inhibitory activity against MRSA with MIC values ranging from 9 to 11 μg/mL, and against E. coli with MIC values in the range of 8−12 μg/mL (Zhang et al. 2019a). Atratumycin (187) was produced by Streptomyces atratus SCSIOZH16, which displayed inhibition against M. tuberculosis H37Ra and H37Rv with MIC values of 3.8 and 14.6 μM, respectively (Sun et al. 2019).
Antimicrobial compounds from Streptomyces sp. from marine seawater
Parimycin (188) and trioxacarcins D–F (189–191) obtained from Streptomyces sp. B8652 had a broad spectrum of antibacterial activity (Maskey et al. 2002, 2004). Streptomyces caelestis afforded new antibacterial citreamicins A (192), B (193), citreaglycon A (194) and dehydrocitreaglycon A (195). 192–195 showed broad spectrum of antibacterial activity against bacterial strains (Liu et al. 2012). Streptcytosine A (196) was discovered from Streptomyces sp. TPU1236A, and it exhibited antibacterial activity against M. smegmatis with an MIC value of 32 μg/mL (Bu et al. 2014).
Antimicrobial compounds from Streptomyces sp. from other marine sources
Streptomyces caniferus CA-271066 afforded caniferolides A–D (197‒200). They showed a broad spectrum of antifungal activity against A. fumigatus ATCC46645 and C. albicans MY1055 with MIC values ranging from 0.5 to 8.0 μg/mL (Pérez-Victoria et al. 2019).
Antimicrobial compounds from Micromonospora species
Antimicrobial compounds from Micromonospora sp. associated with ascidians
Lomaiviticins A (201) (Fig. 8) and B (202) were isolated from Micromonospora lomaivitiensis LL-37I366 and showed inhibitory activities against S. aureus and E. faecium with MIC values in the range of 6 to 25 ng/spot (He et al. 2001). Diazepinomicin (203) was obtained from Micromonospora sp. DPJ12, which exhibited antibacterial activity against Gram-positive bacteria with MICs of about 32 µg/mL (Charan et al. 2004). Micromonohalimane B (204) was isolated from Micromonospora sp. WMMC-218, and 204 inhibited MRSA with an MIC value of 40 μg/mL (Zhang et al. 2016a).
Antimicrobial compounds from Micromonospora sp. associated with sponges
Tetrocarcin Q (205) was discovered from Micromonospora carbonacea LS276, which displayed antibacterial activity against B. subitlis ATCC 63501 with an MIC value of 12.5 µM (Gong et al. 2018).
Antimicrobial compounds from Micromonospora sp. from marine sediments
Butremycin (206) was isolated from Micromonospora sp. K310, which exhibited weak antibacterial activity against S. aureus ATCC 25923, E. coli ATCC 2592 and MRSA (Kyeremeh et al. 2014). Chemical investigation of a culture extract of Micromonospora sp.5–297 led to the discovery of two glycosidic spirotetronates tetrocarcins N (207) and O (208). 207 and 208 showed inhibitory activity against B. subtilis with MIC values of 2 and 64 μg/mL, respectively (Tan et al. 2016). 3,4-Dihydroxy-6,7-dimethyl-quinoline-2-carboxylic acid (209) were isolated from Micromonospora sp. G019, which demonstrated inhibitory activity against E. coli, S. enterica and E. faecalis with the MIC values of 48, 96 and 128 μg/mL, respectively (Thi et al. 2016a). 2-[(5-Methyl-1,4-dioxan-2-yl)methoxy]ethanol (210) showed inhibitory activity against E. faecalis and C. albican with MIC values of 32 and 64 μg/mL, respectively (Thi et al. 2016a). 3-amino-27-demethoxy-27-hydroxyrifamycin S (211), 3-amino-rifamycin S (212), sporalactams A (213) and B (214) were produced by Micromonospora sp. RJA4480. Compounds 211‒214 displayed antibacterial activities against MRSA, E. coli and M. tuberculosis with MIC values of 0.0009, 0.0003 and 0.0009; 0.0008, 0.0001 and 0.0008; 7.0, 1.8 and 0.8; and 1.80, 0.40 and 0.06 μg/mL, respectively (Williams et al. 2017). Microsporanates A–F (215‒220) and tetrocarcin P (221) obtained from Micromonospora harpali SCSIO GJ089 displayed a wide range of antibacterial activities (Gui et al. 2017). Phocoenamicins B (222) and C (223) were isolated from Micromonospora sp. CA-214671, both compounds showed a broad spectrum of antibacterial activities with MIC values ranging from 2 to 64 μg/mL (Pérez-Bonilla et al. 2018).
Antimicrobial compounds from Micromonospora sp. from other marine sources
Thiocoraline (224) was isolated from Micromonospora sp. L-13-ACM2–092, which inhibits the growth of Gram-positive bacteria (Perez et al. 1997).
Antimicrobial compounds from Nocardiopsis species
Antimicrobial compounds from Nocardiopsis sp. from marine sediments
Nocardiopsis dassonvillei produced kahakamide A (225) (Fig. 9), which showed weak antibacterial activity against B. subtilis (Schumacher et al. 2001). Thiopeptide TP-1161 (226) from Nocardiopsis sp. TFS65-07 displayed broad antibacterial activity with MIC values ranging from 0.25 to 1.0 μg/mL (Engelhardt et al. 2010). Nocapyrones E−G (227‒229), were isolated from Nocardiopsis dassonvillei HR10-5, which exhibited inhibitory activities against B. subtilis with MIC values of 26, 14 and 12 μM, respectively (Fu et al. 2011). Nocarimidazoles A (230) and B (231), were produced by Nocardiopsis sp. CNQ115. They displayed antimicrobial activities against B. subtilis with an equal MIC value of 64 μg/mL. Compound 231 displayed antimicrobial activity against S. epidermidis with an MIC value of 64 μg/mL (Leutou et al. 2015). Three α-pyrones 4-deoxyphomapyrone C (232), 4-deoxy-11-methylphomapyrone C (233) and 10-hydroxymucidone (234) were produced by Nocardiopsis sp. SCSIO 10419. Compound 232 displayed antibacterial activity against B. subtilis SCSIO BS01 with an MIC value of 64 μg/mL. Compound 233 and 234 displayed antibacterial activities against M. luteus with the same MIC value of 64 μg/mL (Zhang et al. 2016b). 2-[(2R-Hydroxypropanoyl)amino] benzamide (235) was isolated from Nocardiopsis sp. G057, which displayed inhibitory activity against E. coli with an MIC value of 16 μg/mL (Thi et al. 2016b). Nocazine G (236) was produced by Nocardiopsis sp. YIM M13066, which possessed inhibitory activity against B. subtilis ATCC 6051 with an MIC value of 25.8 μM (Sun et al. 2017). Fluvirucin B6 (237) was isolated from Nocardiopsis sp. CNQ-115, which exhibited inhibitory activity against B. subtilis, K. rhizophila and S. aureus with MIC values of 64, 32 and 32 μg/L, respectively (Leutou et al. 2018). Terretonin N (238) obtained from Nocardiopsis sp. LGO5 had a broad spectrum of antibacterial activity against bacteria (Hamed et al. 2018b).
Antimicrobial compounds from Nocardiopsis sp. associated with sponges
Nocardiopsistins A−C (239‒241), were isolated from Nocardiopsis sp. HB-J378, which showed antibacterial activity against MRSA with MIC values ranging from 3.12 to 12.5 μg/mL (Xu et al. 2018).
Antimicrobial compounds from other marine actinomycetes
Antimicrobial compounds from other actinomycetes associated with sponges
2,4,4′-Trichloro-28-hydroxydiphenylether (242) was isolated from Micrococcus luteus, which showed a broad spectrum of antibacterial activity with MIC values ranging from 16 to 64 μg/mL (Bultel-Poncé et al. 1998). Microluside A (243) was obtained from a culture of Micrococcus sp. EG45, which displayed antimicrobial activity against E. faecalis JH212 and S. aureus NCTC 8325 with MIC values of 10 and 13 μM, respectively (Eltamany et al. 2014). PM18110448 (Kocurin) (244) discovered from Kocuria palustris demonstrated a broad spectrum of antibacterial activity (Martín et al. 2013). A study of Actinokineospora spheciospongiae DSM45935T led to the identification of actinokineosin (245), which exhibited antibacterial activity against M. luteus with an inhibition zone diameter of 8.0 mm at 50 μg/disk (Takasaka et al. 2017).
Antimicrobial compounds from other actinomycetes associated with other marine animals
Saccharothrix espanaensis An 113 produced saccharothrixins A−C (246‒248), which showed modest antibacterial activity (Kalinovskaya et al. 2008). Arenjimycin (249) from Salinispora arenicola CNR-647 displayed broad antibacterial activity (Asolkar et al. 2010). Solwaraspora sp. WMMB329 yielded solwaric acids A and B (250 and 251). Both compounds were active against E. coli, MRSA, MSSA and P. aeruginosa with MIC values of 128, 32, 64, 128 µM and 128, 32, 64, 128 µM, respectively (Ellis et al. 2014). Forazoline A (252) was isolated from Actinomadura sp. WMMB-499, which exhibited inhibitory activity against C. albicans with an MIC value of 16 μg/mL (Wyche et al. 2014). (11S,15R)-11-Hydroxycurvularin (253) and (11R,15R)-11-hydroxycurvularin (254) were obtained from Pseudonocardia sp. HS7. They showed antibacterial activity against E. coli with an equal MIC value of 20 μg/mL (Ye et al. 2016). Actinomadura sp. WMMB499 yielded ecteinamycin (255) (Fig. 10), which showed antibacterial activity against E. coli, S. aureus (MRSA and MSSA), and P. aeruginosa with MIC values of 16, 0.125 and 8 μg/mL, respectively. Compound 255 exhibited inhibition against C. difficile with an MIC value of 0.059−0.117 μg/mL (Wyche et al. 2017).
Antimicrobial compounds from other actinomycetes associated with mangroves and algae
Lechevalieria aerocolonigenes K10-0216 afforded pyrizomicins A and B (256, 257). They showed broad spectrum of antimicrobial activity (Kimura et al. 2018). Kocuria marina CMG S2 afforded kocumarin (258), which showed activity against MRSA with an MIC value of 10−15 μg/mL (Uzair et al. 2018).
Antimicrobial compounds from other actinomycetes associated with marine sediments
Cultivation of Actinomadura sp. M045 produced three new phenoxazin-3-one antibiotics chandrananimycins A–C (259–261). Compounds 259 and 260 exhibited inhibitory activity against Mucor meihei with inhibition zone diameters of 11 and 12 mm at 20 μg/platelet, respectively. Compound 261 showed activity at 20 μg/platelet against B. subtilis, Mucor meihei and S. aureus with inhibition zone diameters of 23, 27 and 22 mm, respectively (Maskey et al. 2003). Abyssomicin C (262) was obtained from Verrucosispora sp. AB-18-032, which exhibited antibacterial activity against S. aureus N315 and S. aureus Mu50s with MIC values of 4 and 13 μg/mL, respectively (Bister et al. 2004). Chemical investigation of a culture extract of Marinispora sp. CNQ-140 led to the discovery of marinomycins A−D (263−266). These compounds showed inhibitory activity against MRSA with MIC90 values of 0.13, 0.25, 0.25 and 0.25 μM, respectively. Compound 264 showed inhibitory activity against VRFE and C. albicans with MIC90 values of 0.13 and 7.8 μM, respectively (Kwon et al. 2006). Marinispora sp. CNQ-140 produced marinisporolide A (267). 267 displayed antifungal activity against C. albicans with an MIC value of 22 μg/mL (Kwon et al. 2009). Atrop-abyssomicin C (268) was obtained from Verrucosispora sp. AB-18-032, which showed antibacterial activity against MRSA N315 with an MIC value of 2.67 μg/mL (Keller et al. 2007). Marinispora NPS008920 yielded lipoxazolidinones A‒C (269‒271). These three compounds were active against S. aureus ATCC 29213 (MSSA) and E. faecalis ATCC 29212 (VSE) with MIC values of 0.9, 6.0 and 4.0; and 1.0, 3.0 and 2 μg/mL, respectively. Compound 269 was also active against H. influenza with an MIC value of 12 μg/mL (Macherla et al. 2007). Lynamicins A–E (272–276) were isolated from Marinispora sp. NPS12745, which exhibited inhibitory activity against MRSA and vancomycin-resistant E. faecium with MIC values ranging from 1.8 to 57.0 μg/mL (McArthur et al. 2008). Cultivation of Verrucosispora maris AB-18–032 produced proximicins B and C (277 and 278). Compound 277 showed antibacterial activity against Brevibacillus brevis DSM with an inhibition zone diameter of 12 mm at 0.3 mg/mL, Compound 278 exhibited a slight inhibition against Brevibaccillus brevis DSM30 (Fiedler et al. 2008). Salinisporamycin (279) was isolated from a culture of Salinispora arenicora YM23-082, which displayed antimicrobial activity against B. subtilis IFO 3134 and Salinispora aureus IFO12732 with MIC values of 4.1 and 0.46 μg/mL, respectively (Matsuda et al. 2009). Culture of Salinispora arenicola yielded saliniquinone A (280), which showed weak activity against MRSA (Murphy et al. 2010). Pseudonocardians A–C (281–283) were ontained from Pseudonocardia sp. SCSIO 01299, which exhibited inhibitory activities against S. aureus ATCC 29213, E. faecalis ATCC 29212 and B. thuringensis SCSIO BT01 with MIC values ranging from 1 to 4 μg/mL (Li et al. 2011). Actinoalloteichus sp. NPS702 afforded neomaclafungins A–I (284–292) (Fig. 11). These compounds showed antifungal activity against Trichophyton mentagrophytes (ATCC 9533) with MIC values ranging from 1 to 3 μg /mL (Sato et al. 2012). Marthiapeptide A (293) was isolated from Marinactinospora thermotolerans SCSIO 00652, which inhibited the growth of Gram-positive bacteria with MIC values ranging from 2 to 8 μg/mL (Zhou et al. 2012). 1-(10-aminodecyl) pyridinium salt antibiotic (294) was purified from Amycolatopsis alba var. nov. DVR D4, which demonstrated inhibitory activity against Gram-positive and Gram-negative bacteria with MIC values ranging from 70 to 160 μg/mL (Dasari et al. 2012). 3-[(6-Methylpyrazin-2-yl)methyl]-1H-indole (295) was obtained from Serinicoccus profundi sp. nov., which displayed weak antibacterial activity against S. aureus ATCC 25923 with an MIC value of 96 μg/mL (Yang et al. 2013). Glycerol 1-hydroxy-2,5-dimethyl benzoate (296) was isolated from Verrucosispora sp. MS100047, which exhibited inhibitory activity against MRSA with an MIC value of 12.5 μg/mL (Huang et al. 2016). Kribellosides A‒D (297‒300) were discovered from Kribbella sp. MI481-42F6 and they inhibited S. cerevisiae with MICs ranging from 3.12 to 100 μg/mL (Igarashi et al. 2017). 5,6-Dihydro-1,8-dihydroxy-3-methylbenz[a]anthracene-7,12-quinone (301) was separated from Actinomadura sp. DS-MS-114, which was active against S. aureus NBRC12732 with an inhibition zone diameter of 12.7 mm at 100 μg/mL (Kurata et al. 2017). Kendomycins B–D (302−304) obtained from Verrucosispora sp. SCSIO 07399 had a broad spectrum of antibacterial activity against S. aureus ATCC 29213, S. aureus 745524, MRSA shhs-A1, E. faecalis ATCC 29212, B. subtilis BS01 and B. thuringiensis BT01 with MIC values ranging from 0.5 to 8.0 μg/mL (Zhang et al. 2019b). Salinaphthoquinones A–D (305−308) were isolated from Salinispora arenicola BRA-213, they showed antibacterial activities against S. aureus and E. faecalis with MIC values ranging from 16 to 125 μg/mL (da Silva et al. 2019).
Antimicrobial compounds from other actinomycetes from other marine sources
Maduralide (309) was obtained from an unidentified marine bacterium of the order Actinomycetales, which displayed weak antibacterial activity against B. subtilis (Pathirana et al. 1991). Taromycin A (310) was isolated from Saccharomonospora sp. CNQ-490, which exhibited inhibitory activity against MRSA and Enterococcus faecalis 613D with MIC values ranging from 6 to 100 μM (Yamanaka et al. 2014). Pseudonocardia carboxydivorans M-227 afforded branimycins B (311) and C (312). They showed a broad spectrum of antibacterial activities (Braña et al. 2017b). Thermoactinoamide A (313) was discovered from Thermoactinomyces vulgaris ISCAR 2354 and was active against S. aureus ATCC 6538 with an MIC value of 35 μM (Teta et al. 2017).
Conclusion
According to the statistic results (Table 1, Fig. 12), the investigation of antimicrobial compounds from marine-derived actinomycetes could be dated back to 1976 when aplasmomycin A (52) was isolated from Streptomyces griseus SS-20 (Table 2) (Okami et al. 1976). Until the end of 2019, 313 new antimicrobial compounds derived from marine actinomycetes have been reported. Since 2016, more secondary metabolites have been isolated from marine actinomyces than ever before except 2007 and 2009.
These new marine natural products from actinomycetes have different types of structural skeletons including nitrogen-containing compounds, sterols and terpenoids, polyketides, and others (Fig. 13). Polyketides and nitrogen-containing compounds (e.g., alkaloids and peptides) are the two main classes (Fig. 13). Because of high halogen concentrations in the Ocean when compared with that on Land, marine actinomyces produced more halogen-containing compounds than their terrestrial counterparts. None of the terpenoids and steroids among the 313 compounds cited in this review article showed potent antimicrobial activity when compared with the other classes of compounds. Compounds 74 and 76, halogenated alkaloids each with two pyrrolphenone moieties inhibited MRSA with an MIC value less than 1 μg/mL (Hughes et al. 2008, 2010). Compounds 201, 202 and 211‒214 are polyketides-derived 1,4-naphthoquinone alkaloids. Compounds 201 and 202 inhibited S. aureus and E. faecium with MIC values ranging from 6 to 25 ng/spot (He et al. 2001). Compounds 211‒214 inhibited MRSA, E.coli and M. tuberculosis with MIC values in the range of 0.3–0.9, 0.1–0.8, and 60–1800 ng/mL, respectively (Williams et al. 2017). Compounds 16‒19 are bicyclic nitrogen-containing compounds each with a phenoxazine bridge. One cyclic peptide fragment (threonine-valine-proline-glycine-valine) was connected to one aromatic ring through an amide bond, and another cyclic peptide fragment (threonine-valine-proline-glycine-valine) was connected to another aromatic ring also through an amide bond. Compounds 16‒19 inhibited MRSA with MIC values less than 1.0 μg/mL (Jiao et al. 2018). Compound 128, a cyclic peptide, exhibited potent antibacterial activity at nanomolar concentrations (Raju et al. 2014). Cyclic peptides 129‒133 inhibited M. luteus with MIC values in the range of 0.061–4.00 μg/mL (Zhou et al. 2014). Compounds 169‒171 are cyclic peptides with some nonstandard amino acids (169 and 171) or hybrids of polyketide and peptide (170). Compounds169 and 171 strongly inhibited M. avium JCM15430, M. intracellulare JCM6384 and M. bovis BCG Pasteur with MIC values in the range of 12 to 780 ng/mL (Hosoda et al. 2019). Besides 170 (hybrids of polyketide and peptide), 201, 202 and 211‒214 (1,4-naphthoquinone alkaloids derived from polyketides), some other polyketides (for examples, 25, 32‒34, 122, 255, and 263‒266) also demonstrated potent antimicrobial activity. Compounds 32‒34 are polyketide anthraquinone derivatives, among which compounds 32 and 33 inhibited MRSA with IC50 values of 0.15 and 0.36 μM, respectively (Socha et al. 2006). Compound 255 is a polyketide derived polyether. It inhibited MRSA, MSSA and C. difficile with MIC values in the range of 59‒125 ng/mL (Wyche et al. 2017). The macrolides 263‒266 are polyketide polyenes, and they inhibited MRSA with MIC90 values in the range of 0.13‒0.25 μM. Other two macrolides 25 (Rodríguez et al. 2018) and 122 (Jang et al. 2013) also exhibited antibacterial activity at ng/mL level. Glycosylated macrolides 135 and 136 inhibited B. subtilis, E. coli, P. aeruginosa, S. aureus and S. cerevisiae with MIC values in the range of 0.027 to 0.22 μM (Mondol and Shin 2014).
Marine actinomycetes are efficient producers of new secondary metabolites. The numbers of antimicrobial compounds from marine Streptomyces sp., Micromonospora sp., Nocardiopsis sp. and the other actinomycetes except Streptomyces sp., Micromonospora sp., and Nocardiopsis sp. were 200, 24, 17 and 72, respectively (Fig. 14), among which about 64% were produced by Streptomyces sp. Other actinomycetes (for examples, Micromonospora, Nocardiopsis, Salinispora and Pseudonocardia) are also prolific producers of secondary metabolites in the marine environment. The numbers of antibacterial and anti-fungal compounds identified from marine actinomycetes are 272 and 70, respectively (Fig. 15).
Scholars in Europe and America, China and other Asian countries published 145, 106 and 50 antimicrobial compounds, respectively (Fig. 16). Different from the antimicrobial study of marine fungi in which Chinese scientists are the most productive in recent years, researchers in Europe and America published 156 antimicrobial compounds from marine actinomycetes, slightly more than scholars in Asia who reported 145 antimicrobial compounds.
J. Nat. Prod. attracted the most contributions (35 articles), followed by J. Antibiot. (29 articles) and Mar. Drugs (24 articles), which accounts for 83% (= 88/107) of all the published papers (Fig. 17). Nearly one-third (31.6%) of all the new antimicrobial compounds were pubished in J. Nat. Prod. followed by Mar. Drugs (12.2%) and by J. Antibiot. (12.1%) (Fig. 18). The dominant host of actinomycetes was marine sediment with a ratio of 69.6% (Fig. 19). Marine animals were also good hosts for actinomycetes (16.9%). Rare marine actinomycetes (for example, Salinispora sp. from deep-sea sediments) in combination of new screening approach will provide more antimicrobial agents.
References
Akhter N, Liu YQ, Auckloo BN, Shi YT, Wang KW, Chen JJ, Wu XD, Wu B (2018) Stress–driven discovery of new angucycline–type antibiotics from a marine Streptomyces pratensis NA–ZhouS1. Mar Drugs 16:331. https://doi.org/10.3390/md16090331
Aksoy SC, Uzel A, Bedir E (2016) Cytosine–type nucleosides from marine–derived Streptomyces rochei 06CM016. J Antibiot (Tokyo) 69:51–56. https://doi.org/10.1038/ja.2015.72
Amagata T, Xiao J, Chen YP, Holsopple N, Oliver AG, Gokey T, Guliaev AB, Minoura K (2012) Creation of an HDAC–based yeast screening method for evaluation of marine–derived actinomycetes: discovery of streptosetin A. J Nat Prod 75:2193–2199. https://doi.org/10.1021/np300640g
Asolkar RN, Maskey RP, Helmke E, Laatsch H (2002) Chalcomycin B, a new macrolide antibiotic from the marine isolate Streptomyces sp. B7064. J Antibiot (Tokyo) 55:893–898. https://doi.org/10.7164/antibiotics.55.893
Asolkar RN, Jensen PR, Kauffman CA, Fenical W (2006) Daryamides A-C, weakly cytotoxic polyketides from a marine–derived actinomycete of the genus Streptomyces Strain CNQ–085. J Nat Prod 69:1756–1759. https://doi.org/10.1021/np0603828
Asolkar RN, Kirkland TN, Jensen PR, Fenical W (2010) Arenimycin, an antibiotic effective against rifampin– and methicillin–resistant Staphylococcus aureus from the marine actinomycete Salinispora arenicola. J Antibiot 63:37–39. https://doi.org/10.1038/ja.2009.114
Bae M, Chung B, Oh KB, Shin J, Oh DC (2015a) Hormaomycins B and C: new antibiotic cyclic depsipeptides from a marine mudflat–derived Streptomyces sp. Mar Drugs 13:5187–5200. https://doi.org/10.3390/md13085187
Bae M, Kim H, Moon K, Nam SJ, Shin J, Oh KB, Oh DC (2015b) Mohangamides A and B, new dilactone-tethered pseudo-dimeric peptides inhibiting Candida albicans isocitrate lyase. Org Lett 17:712–715. https://doi.org/10.1021/ol5037248
Biabani MAF, Laatsh H, Helmke E, Weyland H (1997) δ-Indomycinone: a new member of pluramycin class of antibiotics isolated from marine Streptomyces sp. J Antibiot (Tokyo) 50:874–877. https://doi.org/10.7164/antibiotics.50.874
Bister B, Bischoff D, Ströbele M, Riedlinger J, Reicke A, Wolter FE, Bull AT, Zahner H, Fiedler H, Sussmuth RD (2004) Abyssomicin C-A polycyclic antibiotic from a marine Verrucosispora Strain as an inhibitor of the p-aminobenzoic acid/tetrahydrofolate biosynthesis pathway. Angew Chem Int Edit 43:2574–2576. https://doi.org/10.1002/anie.200353160
Braña AF, Sarmiento-Vizcaíno A, Osset M, Pérez-Victoria I, Martín J, De Pedro N, Díaz C, Vicente F, Reyes F, García LA, Blanco G (2017a) Lobophorin K, a new natural product with cytotoxic activity produced by Streptomyces sp. M-207 associated with the deep–sea coral Lophelia pertusa. Mar Drugs 15:144. https://doi.org/10.3390/md15050144
Braña AF, Sarmiento-Vizcaíno A, Pérez-Victoria I, Otero L, Femandez J, Palacios J, Martin J, Ceuz MDL, Diaz C, Vicente F, Reyes F, Garcia LA, Blanco G (2017b) Branimycins B and C, antibiotics produced by the abyssal actinobacterium Pseudonocardia carboxydivorans M-227. J Nat Prod 80:569–573. https://doi.org/10.1021/acs.jnatprod.6b01107
Braña AF, Sarmiento-Vizcaíno A, Pérez-Victoria I, Martín J, Otero L, Palacios-Gutiérrez JJ, Fernández J, Mohamedi Y, Fontanil T, Salmón M, Cal S, Reyes F, García LA, Blanco G (2019) Desertomycin G, a new antibiotic with activity against Mycobacterium tuberculosis and human breast tumor cell lines produced by Streptomyces althioticus MSM3, isolated from the Cantabrian Sea Intertidal Macroalgae Ulva sp. Mar Drugs 17:114. https://doi.org/10.3390/md17020114
Bultel-Poncé V, Debitus C, Berge JP, Cerceau C, Guyot M (1998) Metabolites from the sponge-associated bacterium Micrococcus luteus. J Mar Biotechnol 6:233–236
Bu YY, Yamazaki H, Ukai K, Namikoshi M (2014) Anti-mycobacterial nucleoside antibiotics from a marine-derived Streptomyces sp. TPU1236A. Mar Drugs 12:6102–6112. https://doi.org/10.3390/md12126102
Cao DT, Nguyen TL, Tran VH, Doan-Thi-Mai H, Vu-thi Q, Nguyen MA, Le-Thi H, Chau VM, Pham VC (2019) Synthesis, structure and antimicrobial activity of novel metabolites from a marine actinomycete in Vietnam's East Sea. Nat Prod Commun 14:121–124. https://doi.org/10.1177/1934578X1901400132
Capon RJ, Skene C, Lacey E, Gill JH, Wicker J, Heiland K, Friedel T (2000) Lorneamides A and B: two new aromatic amides from a southern Australian marine actinomycete. J Nat Prod 63(12):1682–1683. https://doi.org/10.1021/np000241k
Carlson JC, Li SY, Burr DA, Sherman DH (2009) Isolation and characterization of tirandamycins from a marine-derived Streptomyces sp. J Nat Prod 72:2076–2079. https://doi.org/10.1021/np9005597
Charan RD, Schlingmann G, Janso JE, Bernan VS, Feng XD, Carter GT (2004) Diazepinomicin, a new antimicrobial alkaloid from a marine Micromonospora sp. J Nat Prod 67:1431–1433. https://doi.org/10.1021/np040042r
Chen CX, Wang J, Guo H, Hou W, Yang RB, Liu M, Dai H, Liu X, Song F, Zhang L (2013) Three antimycobacterial metabolites identified from a marine–derived Streptomyces sp. MS100061. Appl Microbiol Biotechnol 97:3885–3892. https://doi.org/10.1007/s00253-012-4681-0
Chen H, Cai K, Yao R (2018a) A new macrolactam derivative from the marine actinomycete HF-11225. J Antibiot 71:477–479. https://doi.org/10.1038/s41429-017-0021-z
Chen S, Zhang D, Chen M, Zhang Z, Lian XY (2018b) A rare diketopiperazine glycoside from marine-sourced Streptomyces sp. ZZ446. Nat Prod Res. https://doi.org/10.1080/14786419.2018.1544978
Cheng YB, Jensen PR, Fenical W (2013) Cytotoxic and antimicrobial napyradiomycins from two marine-derived, MAR4 Streptomyces strains. Eur J Org Chem 2013:3751–3757. https://doi.org/10.1002/ejoc.201300349
Cho KW, Seo YW, Yoon TM, Shin JH (1999) Purification and structure determination of antifungal phospholipids from a marine Streptomyces. J Microbiol Biotechnol 9:709–715
Cong Z, Huang X, Liu Y, Liu Y, Wang P, Liao S, Wang B, Zhou X, Huang D, Wang J (2019) Cytotoxic anthracycline and antibacterial tirandamycin analogues from a marine-derived Streptomyces sp. SCSIO 41399. J Antibiot 72:45–49. https://doi.org/10.1038/s41429-018-0103-6
Da Silva AB, Silveira ER, Wilke DV, Ferreira EG, Costalotufo LV, Torres MCM, Ayala AP, Costa WS, Canuto KM, Araujonobre ARD, Araujo AJ, Filho JDBM, Pessoa ODL (2019) Antibacterial salinaphthoquinones from a strain of the bacterium Salinispora arenicola recovered from the marine sediments of St. Peter and St. Paul Archipelago. Brazil J Nat Prod 82:1831–1838. https://doi.org/10.1021/acs.jnatprod.9b00062
Dalisay DS, Williams DE, Wang XL, Centko R, Chen J, Andersen RJ (2013) Marine sediment-derived Streptomyces bacteria from british columbia, canada are a promising microbiota resource for the discovery of antimicrobial natural products. PLoS ONE 8:1–14. https://doi.org/10.1371/journal.pone.0077078
Dasari VRRK, Muthyala MKK, Nikkuf MY, Donthireddy SRR (2012) Novel Pyridinium compound from marine actinomycete, Amycolatopsis alba var. nov. DVR D4 showing antimicrobial and cytotoxic activities in vitro. Microbiol Res 167:346–351. https://doi.org/10.1016/j.micres.2011.12.003
Ding L, Maier A, Fiebig HH, Görls H, Lin WH, Peschel G, Hertweck C (2011a) Divergolides A-D from a mangrove endophyte reveal an unparalleled plasticity in ansa–macrolide biosynthesis. Angew Chem Int Ed 50:1630–1634. https://doi.org/10.1002/anie.201006165
Ding L, Maier A, Fiebig HH, Lin WH, Hertweck C (2011b) A family of multicyclic indolosesquiterpenes from a bacterial endophyte. Org Biomol Chem 9:4029–4031. https://doi.org/10.1039/C1OB05283G
Ding L, Maier A, Fiebig HH, Lin WH, Peschel G, Hertweck C (2012) Kandenols A−E, eudesmenes from an endophytic Streptomyces sp. of the mangrove tree Kandelia candel. J Nat Prod 75:2223–2227. https://doi.org/10.1021/np300387n
Ding WJ, Zhang SQ, Wang JH, Lin YX, Liang QX, Zhao WJ, Li CY (2013) A new di-O-prenylated flavone from an actinomycete Streptomyces sp. MA-12. J Asian Nat Prod Res 15:209–214. https://doi.org/10.1080/10286020.2012.751979
Djinni I, Defant A, Kecha M, Mancini I (2013) Antibacterial polyketides from the marine alga–derived endophitic Streptomyces sundarbansensis: a study on hydroxypyrone tautomerism. Mar Drugs 11:124–135. https://doi.org/10.3390/md11010124
El-Gendy MMA, Shaaban M, Shaaban KA, El-Bondkly AM, Laatsch H (2008) Essramycin: a first triazolopyrimidine antibiotic isolated from nature. J Antibiot (Tokyo) 61:149–157. https://doi.org/10.1038/ja.2008.124
Ellis GA, Wyche TP, Fry CG, Braun DR, Bugni TS (2014) Solwaric acids A and B, antibacterial aromatic acids from a marine Solwaraspora sp. Mar Drugs 12:1013–1022. https://doi.org/10.3390/md12021013
Eltamany EE, Abdelmohsen UR, Ibrahim AK, Hassanean HA, Hentschel U, Ahmed SA (2014) New antibacterial xanthone from the marine sponge–derived Micrococcus sp. EG45. Bioorg Med Chem Lett 24:4939–4942. https://doi.org/10.1016/j.bmcl.2014.09.040
Engelhardt K, Degnes KF, Kemmler M, Bredholt H, Fjaervik E, Klinkenberg G, Sletta H, Ellingsen TE, Zotchev SB (2010) Production of a new thiopeptide antibiotic, TP-1161, by a marine Nocardiopsis species. Appl Environ Microb 76:4969–4976. https://doi.org/10.1128/AEM.00741-10
Fiedler HP, Bruntner C, Riedlinger J, Bull AT, Knutsen G, Goodfellow M, Jones A, Maldonado LA, Pathomaree W, Beil W, Schneider K, Keller S, Sussmuth RD (2008) Proximicin A, B and C, novel aminofuran antibiotic and anticancer compounds isolated from marine strains of the actinomycete Verrucosispora. J Antibiot 61:158–163. https://doi.org/10.1038/ja.2008.125
Fu P, Liu PP, Qu HJ, Wang Y, Chen DF, Wang H, Li J, Zhu WM (2011) α-Pyrones and diketopiperazine derivatives from the marine-derived actinomycete Nocardiopsis dassonvillei HR10–5. J Nat Prod 74:2219–2223. https://doi.org/10.1021/np200597m
Gong T, Zhen X, Li XL, Chen JJ, Chen TJ, Yang JL, Zhu P (2018) Tetrocarcin Q, a new spirotetronate with a unique glycosyl group from a marine–derived actinomycete Micromonospora carbonacea LS276. Mar Drugs 16:74. https://doi.org/10.3390/md16020074
Gui C, Zhang SW, Zhu XC, Ding WJ, Huang HB, Gu YC, Duan YW, Ju JH (2017) Antimicrobial spirotetronate metabolites from marine-derived Micromonospora harpali SCSIO GJ089. J Nat Prod 80:1594–1603. https://doi.org/10.1021/acs.jnatprod.7b00176
Hamed A, Abdel-Razek AS, Frese M, Stammler H, Elhaddad AF, Ibrahim TM, Sewald N, Shaaban M (2018a) Terretonin N: a new meroterpenoid from Nocardiopsis sp. Molecules 23:299. https://doi.org/10.3390/molecules23020299
Hamed A, Abdel-Razek AS, Frese M, Wibberg D, Elhaddad AF, Ibrahim TM, Kalinowski J, Sewald N, Shaaban M (2018b) N-Acetylborrelidin B: a new bioactive metabolite from Streptomyces mutabilis sp. MII Z Naturforsch C 73:49–57. https://doi.org/10.1515/znc-2017-0140
Han Z, Xu Y, McConnell O, Liu L, Li Y, Qi S, Huang X, Qian P (2012) Two antimycin A analogues from marine-derived actinomycete Streptomyces lusitanus. Mar Drugs 10:668–676. https://doi.org/10.3390/md10030668
Hassan HM, Degen D, Jang KH, Ebright RH, Fenical W (2015) Salinamide F, new depsipeptide antibiotic and inhibitor of bacterial RNA polymerase from a marine-derived Streptomyces sp. J Antibiot 68:206–209. https://doi.org/10.1038/ja.2014.122
He HY, Ding WD, Bernan VS, Richardson AD, Ireland CM, Greenstein M, Ellestad GA, Carter GT (2001) Lomaiviticins A and B, potent antitumor antibiotics from Micromonospora lomaivitiensis. J Am Chem Soc 123:5362–5363. https://doi.org/10.1021/ja010129o
Hosoda K, Koyama N, Kanamoto A, Tomoda H (2019) Discovery of nosiheptide, griseoviridin, and etamycin as potent anti-mycobacterial agents against Mycobacterium avium complex. Molecules 24:1495. https://doi.org/10.3390/molecules24081495
Hu Y, Wang M, Wu C, Tan Y, Li J, Hao X, Duan Y, Guan Y, Shang X, Wang Y, Xiao C, Gan M (2018) Identification and proposed relative and absolute configurations of niphimycins C-E from the marine-derived Streptomyces sp. IMB7–145 by genomic analysis. J Nat Prod 81:178–187. https://doi.org/10.1021/acs.jnatprod.7b00859
Huang P, Xie F, Ren B, Wang Q, Wang J, Wang Q, Abodeimageed WM, Liu MM, Han JY, Oyeleye A, Shen JZ, Song FH, Dai HQ, Liu XT, Zhang LX (2016) Anti-MRSA and anti-TB metabolites from marine-derived Verrucosispora sp. MS100047. Appl Microbiol Biot 100:7437–7447. https://doi.org/10.1002/anie.200353160
Hughes CC, Prieto-Davo A, Jensen PR, Fenical W (2008) The marinopyrroles, antibiotics of an unprecedented structure class from a marine Streptomyces sp. Org Lett 10:629–631. https://doi.org/10.1021/ol702952n
Hughes CC, Kauffman CA, Jensen PR, Fenical W (2010) Structures, reactivities, and antibiotic properties of the marinopyrroles A-F. J Org Chem 75:3240–3250. https://doi.org/10.1021/jo1002054
Igarashi M, Sawa R, Yamasaki M, Hayashi C, Umekita M, Hatano M, FuJiwara T, Mizumoto K, Nomoto A (2017) Kribellosides, novel RNA 5′–triphosphatase inhibitors from the rare actinomycete Kribbella sp. MI481-42F6. J Antibiot 70:582–589. https://doi.org/10.1038/ja.2016.161
Imamura N, Nishijima M, Adachi K, Sano H (1993) Novel antimycin antibiotics, urauchimycins A and B, produced by marine actinomycete. J Antibiot (Tokyo) 46:241–246. https://doi.org/10.7164/antibiotics.46.241
Ivanova V, Oriol M, Montes MJ, García A, Guinea J (2001) Secondary metabolites from a Streptomyces strain isolated from Livingston Island, Antarctica. Z Naturforsch C 5:1–5. https://doi.org/10.1515/znc-2001-1-201
Jang KH, Nam SJ, Locke JB, Kauffman CA, Beatty DS, Paul LA, Fenical W (2013) Anthracimycin, a potent anthrax antibiotic from a marine–derived actinomycete. Angew Chem Int Ed 52:7822–78241. https://doi.org/10.1002/anie.201302749
Jiang ZD, Jensen PR, Fenical W (1997) Actinoflavoside, a novel flavonoid-like glycoside produced by a marine bacterium of the genus Streptomyces. Tetrahedron Lett 38:5065–5068. https://doi.org/10.1016/S0040-4039(97)01127-1
Jiang YJ, Zhang DS, Zhang HJ, Li JQ, Ding WJ, Xu CD, Ma ZJ (2018) Medermycin-type naphthoquinones from the marine–derived Streptomyces sp. XMA39. J Nat Prod 81:2120–2124. https://doi.org/10.1021/acs.jnatprod.8b00544
Jiao WH, Yuan W, Li ZY, Li J, Li L, Sun JB, Gui YH, Wang J, Ye BP, Lin HW (2018) Anti-MRSA actinomycins D1–D4 from the marine sponge-associated Streptomyces sp. LHW52447. Tetrahedron 74:5914–5919. https://doi.org/10.1016/j.tet.2018.08.023
Kalinovskaya NI, Kalinovsky AI, Romanenko LA, Pushilin MA, Dmitrenok PS, Kuznetsova TA (2008) New angucyclinones from the marine mollusk associated actinomycete Saccharothrix espanaensis An 113. Nat Prod Commun 3:10. https://doi.org/10.1177/1934578x0800301006
Keller S, Nicholson G, Drahl C, Sorensen EJ, Fiedler H, Sussmuth RD (2007) Abyssomicins G and H and atrop–abyssomicin C from the marine Verrucosispora strain AB-18-032. J Antibiot 60:391–394. https://doi.org/10.1038/ja.2007.54
Khalil ZG, Raju R, Piggott AM, Salim AA, Blumenthal A, Capon RJ (2015) Aranciamycins I and J, antimycobacterial anthracyclines from an Australian marine-derived Streptomyces sp. J Nat Prod 78:949–952. https://doi.org/10.1021/acs.jnatprod.5b00095
Kim DG, Moon K, Kim SH, Park SH, Lee SK, Oh KB, Shin J, Oh DC (2012) Bahamaolides A and B, antifungal polyene polyol macrolides from the marine actinomycete Streptomyces sp. J Nat Prod 75:959–967. https://doi.org/10.1021/np3001915
Kimura T, Inahashi Y, Matsuo H, Suga T, Iwatsuki M, Shiomi K, Takahashi Y, Omura S, Nakashima T (2018) Pyrizomicins A and B: Structure and bioactivity of new thiazolyl pyridines from Lechevalieria aerocolonigenes K10–0216. J Antibiot 71:606–608. https://doi.org/10.1038/s41429-018-0038-y
Kunz AL, Labes A, Wiese J, Bruhn T, Bringmann G, Imhoff JF (2014) Nature's lab for derivatization: new and revised structures of a variety of streptophenazines produced by a sponge-derived Streptomyces strain. Mar Drugs 12:1699–1714. https://doi.org/10.3390/md12041699
Kurata A, Sugiura M, Kokoda K, Tsujimoto H, Numata T, Kato C, Nakasone K, Kishimoto N (2017) Taxonomy of actinomycetes in the deep–sea Calyptogena communities and characterization of the antibacterial compound produced by Actinomadura sp. DS-MS-114. Biotechnol Biotechnol Equip 31:1000–1006. https://doi.org/10.1080/13102818.2017.1342563
Kwon HC, Kauffman CA, Jensen PR, Fenical W (2006) Marinomycins A−D, antitumor–antibiotics of a new structure class from a marine actinomycete of the recently discovered genus “Marinispora”. J Am Chem Soc 128:1622–1632. https://doi.org/10.1002/chin.200624214
Kwon HC, Kauffman CA, Jensen PR, Fenical W (2009) Marinisporolides, polyene-polyol macrolides from a marine actinomycete of the new genus Marinispora. J Org Chem 74:675–684. https://doi.org/10.1002/chin.200920193
Kyeremeh K, Acquah KS, Sazak A, Houssen WE, Tabudravu JN, Deng H, Jaspars M (2014) Butremycin, the 3–hydroxyl derivative of ikarugamycin and a protonated aromatic tautomer of 5′-methylthioinosine from a Ghanaian Micromonospora sp. K310. Mar Drugs 12:999–1012. https://doi.org/10.3390/md12020999
Lacret R, Oves-Costales D, Gomez C, Gómez C, Diaz C, La Cruz MD, Perezvictoria I, Vicente F, Genilloud O, Reyes F (2015) New ikarugamycin derivatives with antifungal and antibacterial properties from Streptomyces zhaozhouensis. Mar Drugs 13:128–140. https://doi.org/10.3390/md13010128
Leutou AS, Yang I, Kang H, Seo EK, Nam S, Fenical W (2015) Nocarimidazoles A and B from a marine-derived actinomycete of the genus Nocardiopsis. J Nat Prod 78:2846–2849. https://doi.org/10.1021/acs.jnatprod.5b00746
Leutou AS, Yang I, Le TC, Hahn D, Lim K, Nam S, Fenical W (2018) Fluvirucin B6, a new macrolactam isolated from a marine-derived actinomycete of the genus Nocardiopsis. J Antibiot 71:609–611. https://doi.org/10.1038/s41429-018-0033-3
Li S, Tian X, Niu S, Zhang WJ, Chen YC, Zhang HB, Yang XB, Zhang WM, Li WJ, Zhang S, Ju JH, Zhang CS (2011) Pseudonocardians A-C, new diazaanthraquinone derivatives from a deap-sea actinomycete Pseudonocardia sp. SCSIO 01299. Mar Drugs 9:1428–1439. https://doi.org/10.3390/md9081428
Lian XY, Zhang ZZ (2013) Indanomycin–related antibiotics from marine Streptomyces antibioticus PTZ0016. Nat Prod Res 27:2161–2167. https://doi.org/10.1080/14786419.2013.793688
Liang Y, Xie X, Chen L, Yan SL, Ye XW, Anjum KA, Huang HC, Lian XY, Zhang ZZ (2016) Bioactive polycyclic quinones from marine Streptomyces sp. 182SMLY. Mar Drugs 14:1–11. https://doi.org/10.3390/md14010010
Lin ZJ, Koch M, Pond CD, Mabeza G, Seronay RA, Concepcion GP, Barrows LR, Olivera BM, Schmidt EW (2014) Structure and activity of lobophorins from a turrid mollusk-associated Streptomyces sp. J Antibiot (Tokyo) 67:121–126. https://doi.org/10.1038/ja.2013.115
Liu LL, Xu Y, Han Z, Li YX, Lu L, Lai PY, Zhong JL, Guo XR, Zhang XX, Qian PY (2012) Four new antibacterial xanthones from the marine-derived actinomycetes Streptomyces caelestis. Mar Drugs 10:2571–2583. https://doi.org/10.3390/md10112571
Macherla VR, Liu J, Sunga M, White DJ, Grodberg J, Teisan S, Lam KS, Potts BCM (2007) Lipoxazolidinones A, B, and C: antibacterial 4-oxazolidinones from a marine actinomycete isolated from a Guam marine sediment. J Nat Prod 70:1454–1457. https://doi.org/10.1021/np0702032
Manam RR, Teisan S, White DJ, Nicholson B, Grodberg J, NeuteboomKin STC, Lam KS, Mosca DA, LloydBarbara GK, Potts BCM (2005) Lajollamycin, a Nitro-tetraene Spiro-β-lactone-γ-lactam antibiotic from the marine actinomycete Streptomyces nodosus. J Nat Prod 68:240–243. https://doi.org/10.1021/np049725x
Martín J, Sousa TS, Crespo G, Palomo S, Gonzalez I, Tormo JR, Cruz MDL, Anderson MA, Hill RT, Vicente F, Genilloud O, Reyes F (2013) Kocurin, the true structure of PM181104, an anti-methicillin-resistant Staphylococcus aureus (MRSA) thiazolyl peptide from the marine-derived bacterium Kocuria palustris. Mar Drugs 11:387–398. https://doi.org/10.3390/md11020387
Maskey RP, Helmke E, Fiebig HH, Laatsch H (2002) Parimycin isolation and structure elucidation of a novel cytotoxic 2,3-dihydroquinizarin analogue of γ-indomycinone from a marine Streptomycete. J Antibiot (Tokyo) 55:1031–1035. https://doi.org/10.7164/antibiotics.55.1031s
Maskey RP, Li FC, Qin S, Fiebig HH, Laatsch H (2003) Chandrananimycins A-C: production of novel anticancer antibiotics from a marine Actinomadura sp. isolate M048 by variation of medium composition and growth conditions. J Antibiot 56:622–629. https://doi.org/10.1002/chin.200352223
Maskey RP, Sevvana M, Uson I, Helmke E, Laatsch H (2004) Gutingimycin: a highly complex metabolite from a marine streptomycete. Angew Chem Int Ed 43:1281–1283. https://doi.org/10.1002/anie.200352312
Matsuda S, Adachi K, Matsuo Y, Nukina M, Shizuri Y (2009) Salinisporamycin, a novel metabolite from Salinispora arenicora. J Antibiot 62:519–526. https://doi.org/10.1038/ja.2009.75
McArthur KA, Mitchell SS, Tsueng G, Rheingold AL, White DJ, Grodberg J, Lam KS, Potts BCM (2008) Lynamicins A-E, chlorinated bisindole pyrrole antibiotics from a novel marine actinomycete. J Nat Prod 71:1732–1737. https://doi.org/10.1021/np800286d
Mitova MI, Lang G, Wiese J, Imhoff JF (2008) Subinhibitory concentrations of antibiotics induce phenazine production in a marine Streptomyces sp. J Nat Prod 71:824–827. https://doi.org/10.1021/np800032a
Mondol MAM, Shin HJ (2014) Antibacterial and antiyeast compounds from marine-derived bacteria. Mar Drugs 12:2913–2921. https://doi.org/10.3390/md12052913
Moon K, Chung B, Shin Y, Rheingold AL, Moore CE, Park SJ, Park S, Lee SK, Oh K, Shin J, Oh D (2015) Pentacyclic antibiotics from a tidal mud flat–derived actinomycete. J Nat Prod 78:524–529. https://doi.org/10.1021/np500736b
Motohashi K, Irie K, Toda T, Matsuo Y, Kasai H, Sue M, Furihata K, Seto H (2008) Studies on terpenoids produced by actinomycetes. J Antibiot 61:75–80. https://doi.org/10.1038/ja.2008.113
Murphy BT, Narender T, Kauffman CA, Woolery M, Jersen PR, Fenical W (2010) Saliniquinones A-F, new members of the highly cytotoxic anthraquinone–γ–pyrones from the marine actinomycete Salinispora arenicola. Aust J Chem 63:929–934. https://doi.org/10.1071/CH10068
Niu SW, Li SM, Chen YC, Li S, Chen Y, Tian X, Zhang H, Zhang G, Zhang W, Yang X, Zhang S, Ju J, Zhang C (2011) Lobophorins E and F, new spirotetronate antibiotics from a South China Sea–derived Streptomyces sp SCSIO 01127. J Antibiot 64:711–716. https://doi.org/10.1038/ja.2011.78
Nong XH, Zhang XY, Xu XY, Wang J, Qi SH (2016) Nahuoic acids B-E, polyhydroxy polyketides from the marine-derived Streptomyces sp. SCSGAA 0027. J Nat Prod 79:141–148. https://doi.org/10.1021/acs.jnatprod.5b00805
Ohlendorf B, Schulz D, Erhard A, Nagel K, Imhoff JF (2012) Geranylphenazinediol, an acetylcholinesterase inhibitor produced by a Streptomyces species. J Nat Prod 75:1400–1404. https://doi.org/10.1021/np2009626
Okami Y, Hotta K, Yoshida M, Ikeda D, Kondo S, Umezawa H (1979) New aminoglycoside antibiotics, istamycins A and B. J Antibiot (Tokyo) 32:964–966. https://doi.org/10.7164/antibiotics.32.964
Okami Y, Okazaki T, Kitahara T, Umezawa H (1976) Studies on marine microorganisms. A new antibiotic, aplasmomycin, produced by a streptomycete isolated from shallow sea mud. J Antibiot (Tokyo) 29:1019–1025. https://doi.org/10.7164/antibiotics.29.1019
Pan HQ, Zhang SY, Wang N, Li ZL, Hua HM, Hu JC, Wang SJ (2013) New spirotetronate antibiotics, lobophorins H and I, from a South China Sea-derived Streptomyces sp. 12A35. Mar Drugs 11:3891–3901. https://doi.org/10.3390/md11103891
Pathirana C, Tapiolas D, Jensen PR, Dwight RH, Fenical W (1991) Structure determination of maduralide: a new 24-membered ring macrolide glycoside produced by a marine bacterium (Actinomycetales). Tetrahedron Lett 32:2323–2326. https://doi.org/10.1016/S0040-4039(00)79914-X
Pathirana C, Jensen PR, Dwight R, Fenical W (1992) Rare phenazine L-quinovose esters from a marine actinomycete. J Org Chem 57:740–742. https://doi.org/10.1021/jo00028a060
Perez BJ, Canedo LM, Fernandez PJL, Silva EMV (1997) Thiocoraline, a novel depsipeptide with antitumor activity produced by a marine Micromonospora: II. Physico-chemical properties and structure determination. J Antibiot 50:738–741. https://doi.org/10.7164/antibiotics.50.738
Perez-Bonilla M, Ovescostales D, Cruz MDL, Kokkini M, Martin J, Vicente F, Genilloud O, Reyes F (2018) Phocoenamicins B and C, new antibacterial spirotetronates isolated from a marine Micromonospora sp. Mar Drugs 16:95. https://doi.org/10.3390/md16030095
Pérez-Victoria I, Oves-Costales D, Lacret R, Martín J, Sánchez-Hidalgo M, Díaz C, Cautain B, Vicente F, Genilloud O, Reyes F (2019) Structure elucidation and biosynthetic gene cluster analysis of caniferolides A-D, new bioactive 36-membered macrolides from the marine-derived Streptomyces caniferus CA-271066. Org Biomol Chem 17:2954–2971. https://doi.org/10.1039/C8OB03115K
Poumale HMP, Ngadjui BT, Helmke E, Laatscha H (2006) New anthraquinones from a marine Streptomyces sp. –isolation, structure determination and biological activities. Z Naturforsch B 61:1450–1454. https://doi.org/10.1515/znb-2006-1122
Pusecker K, Laatsch H, Helmke E, Weyland H (1997) Dihydrophencomycin methyl ester, a new phenazine derivative from a marine Streptomycete. J Antibiot (Tokyo) 50:479–483. https://doi.org/10.7164/antibiotics.50.479
Raju R, Piggott AM, Barrientos Diaz LX, Khalil, Z, Capon RJ (2010) Heronapyrroles A−C: farnesylated 2-nitropyrroles from an Australian marine-derived Streptomyces sp. Org Lett 12:5158−5161. https://doi.org/10.1021/ol102162d
Raju R, Piggott AM, Khalil Z, Bernhardt PV, Capona RJ (2012) Heronamycin A: a new benzothiazine ansamycin from an Australian. Tetrahedron Lett 53:1063–1065. https://doi.org/10.1016/j.tetlet.2011.12.064
Raju R, Khalil ZG, Piggott AM, Blumenthal A, Gardiner DL, Skinneradams TS, Capon RJ (2014) Mollemycin A: an antimalarial and antibacterial glycol-hexadepsipeptide-polyketide from an Australian marine-derived Streptomyces sp. (CMB–M0244). Org Lett 16:1716–1719. https://doi.org/10.1021/ol5003913
Rodríguez V, Martín J, Sarmiento-Vizcaíno A, De la Cruz M, García LA, Blanco G, Fernando F (2018) Anthracimycin B, a potent antibiotic against gram-positive bacteria isolated from cultures of the deep-sea actinomycete Streptomyces cyaneofuscatus M–169. Mar Drugs 16:406. https://doi.org/10.3390/md16110406
Ryu MJ, Hwang S, Kim S, Yang I, Oh D, Nam S, Fenical W (2019) Meroindenon and merochlorins E and F, antibacterial meroterpenoids from a marine-derived sediment bacterium of the Genus Streptomyces. Org Lett 21:5779–5783. https://doi.org/10.1021/acs.orglett.9b01440
Sato K, Okazak T, Maeda K, Okami Y (1978) New antibiotics, aplasmomycins B and C. J Antibiot 31:632–635. https://doi.org/10.7164/antibiotics.31.632
Sato S, Iwata F, Yamada S, Katayama M (2012) Neomaclafungins A-I: oligomycin-class macrolides from a marine-derived actinomycete. J Nat Prod 75:1974–1982. https://doi.org/10.1021/np300719g
Schneemann I, Kajahn I, Ohlendorf B, Zinecker H, Erhard A, Nagel K, Wiese J, Imhoff JF (2010) Mayamycin, a cytotoxic polyketide from a Streptomyces strain isolated from the marine sponge Halichondria panicea. J Nat Prod 73:1309–1312. https://doi.org/10.1021/np100135b
Schumacher RW, Harrigan BL, Davidson BS (2001) Kahakamides A and B, new neosidomycin metabolites from a marine-derived actinomycete. Tetrahedron Lett 42:5133–5135. https://doi.org/10.1016/S0040-4039(01)00979-0
Shaaban KA, Helmke E, Kelter G, Fiebig HH, Laatsch H (2011) Glucopiericidin C: a cytotoxic piericidin glucoside antibiotic produced by a marine Streptomyces isolate. J Antibiot (Tokyo) 64:205–209. https://doi.org/10.1038/ja.2010.125
Schumacher RW, Talmage SC, Miller SA, Sarris KE, Davidson BS, Goldberg A (2003) Isolation and structure determination of an antimicrobial ester from a marine sediment-derived bacterium. J Nat Prod 66:1291–1293. https://doi.org/10.1021/np020594e
Sitachitta N, Gadepalli M, Davidson BS (1996) New a-pyrone-containing metabolites from a marine-derived actinomycete. Tetrahedron 52:8073–8080. https://doi.org/10.1016/0040-4020(96)00391-2
Socha AM, Garcia D, Sheffer R, Rowley DC (2006) Antibiotic bisanthraquinones produced by a Streptomycete isolated from a Cyanobacterium. J Nat Prod 69:1070–1073. https://doi.org/10.1021/np050449b
Song YX, Huang HB, Chen YC, Ding J, Zhang Y, Sun A, Zhang W, Ju J (2013) Cytotoxic and antibacterial marfuraquinocins from the deep south china sea–derived Streptomyces niveus SCSIO 3406. J Nat Prod 76:2263–2268. https://doi.org/10.1021/np4006025
Song YX, Li QL, Liu X, Chen YC, Zhang Y, Sun AJ, Zhang WM, Zhang JR, Ju JH (2014) Cyclic hexapeptides from the deep south china sea-derived Streptomyces scopuliridis SCSIO ZJ46 active against pathogenic gram–positive bacteria. J Nat Prod 77:1937–1941. https://doi.org/10.1021/np500399v
Sugiyama R, Nishimura S, Matsumori N, Tsunematsu Y, Hattori A, Kakeya H (2014) Structure and biological activity of 8-deoxyheronamide C from a marine-derived Streptomyces sp.: heronamides target saturated hydrocarbon chains in lipid membranes. J Am Chem Soc 136(14):5209–5212. https://doi.org/10.1021/ja500128u
Sun P, Maloney KN, Nam SJ, Haste NM, Raju R, Aalbersberg W, Jensen PR, Nizet V, Hensler M, Fenical W (2011) Fijimycins A-C, three antibacterial etamycin–class depsipeptides from a marine-derived Streptomyces sp. Bioorg Med Chem 19:6557–6562. https://doi.org/10.1016/j.bmc.2011.06.053
Sun MW, Chen XT, Li WJ, Lu CH, Shen YM (2017) New diketopiperazine derivatives with cytotoxicity from Nocardiopsis sp. YIM M13066. J Antibiot 70:795–797. https://doi.org/10.1038/ja.2017.46
Sun CL, Yang ZJ, Zhang CY, Liu ZY, He JQ, Liu Q, Zhang TY, Ma JY (2019) Genome mining of Streptomyces atratus SCSIO ZH16: discovery of atratumycin and identification of its biosynthetic gene cluster. Org Lett 21:1453–1457. https://doi.org/10.1021/acs.orglett.9b00208
Supong K, Thawai C, Suwanborirux K, Choowong W, Supothina S, Pittayakhajonwut P (2012) Antimalarial and antitubercular C–glycosylated benz[a]anthraquinones from the marine-derived Streptomyces sp. BCC45596. Phytochem Lett 5:651–656. https://doi.org/10.1016/j.phytol.2012.06.015
Takasaka N, Kaweewan I, Ohnishi-Kameyama M, Kodani S (2017) Isolation of a new antibacterial peptide actinokineosin from Actinokineospora spheciospongiae based on genome mining. Lett Appl Microbiol 64:150–157. https://doi.org/10.1111/lam.12693
Tan Y, Hu YY, Wang Q, Zhou HX, Wang YG, Gan ML (2016) Tetrocarcins N and O, glycosidic spirotetronates from a marine-derived Micromonospora sp. identified by PCR-based screening. Rsc Adv 6:91773–91778. https://doi.org/10.1039/C6RA17026A
Teta R, Marteinsson VT, Longeon A, Klonowski AM, Groben R, Bourguetkondracki M, Costantion V, Mangori A (2017) Thermoactinoamide A, an Antibiotic Lipophilic Cyclopeptide from the Icelandic Thermophilic Bacterium Thermoactinomyces vulgaris. J Nat Prod 80:2530–2535. https://doi.org/10.1021/acs.jnatprod.7b00560
Thi QV, Tran VH, Mai HD, Le CV, Hong MLE, Murphy BT, Chau VM, Pham VC (2016a) Secondary metabolites from an Actinomycete from Vietnam's East Sea. Nat Prod Commun 11:401–404. https://doi.org/10.1177/1934578x1601100320
Thi QV, Tran VH, Mai HD, Le CV, Hong MLY, Murphy BT, Chau VM, Pham VC (2016b) Antimicrobial metabolites from a marine–derived Actinomycete in Vietnam's East Sea. Nat Prod Commun 11:49–51. https://doi.org/10.1080/14786419.2018.1468331
Trischman JA, Tapiolas DM, Jensen PR, Dwight R, Fenical W, McKee TC, Ireland CM, Stout TJ, Clardy J (1994) Salinamides A and B: anti–inflammatory depsipeptides from a marine Streptomycete. J Am Chem Soc 116:757–758. https://doi.org/10.1021/ja00081a042
Um S, Choi TJ, Kim H, Kim BY, Kim SH, Lee SK, Oh K, Shin JS, Oh D (2013) Ohmyungsamycins A and B: cytotoxic and antimicrobial cyclic peptides produced by Streptomyces sp. from a volcanic island. J Org Chem 78:12321–12329. https://doi.org/10.1021/jo401974g
Uzair B, Menaa F, Khan BA, Mohammad FV, Ahmad VU, Djeribi R, Menaa B (2018) Isolation, purification, structural elucidation and antimicrobial activities of kocumarin, a novel antibiotic isolated from actinobacterium Kocuria marina CMG S2 associated with the brown seaweed Pelvetia canaliculata. Microbiol Res 206:186–197. https://doi.org/10.1016/j.micres.2017.10.007
Wang Q, Zhang YX, Wang M, Tan Y, Hu XX, He HW, Xiao CL, You XF, Wang YG, Gan ML (2017) Neo–actinomycins A and B, natural actinomycins bearing the 5 H-oxazolo [4, 5-b] phenoxazine chromophore, from the marine-derived Streptomyces sp. IMB094. Sci Rep-UK 7:1–8. https://doi.org/10.1038/s41598-017-03769-8
Williams DE, Dalisay DS, Chen J, Polishchuck EA, Patrick BO, Narula G, Ko M, Avgay Y, Li HX, Magarvey NA, Andersen RJ (2017) Aminorifamycins and sporalactams produced in culture by a Micromonospora sp. isolated from a Northeastern-Pacific marine sediment are potent antibiotics. Org Lett 19:766–769. https://doi.org/10.1021/acs.orglett.6b03619
Wilson MC, Nam SJ, Gulder TA, Kauffman CA, Jensen PR, Fenical W, Moore BS (2011) Structure and biosynthesis of the marine Streptomycete ansamycin ansalactam A and its distinctive branched chain polyketide extender unit. J Am Chem Soc 133:1971–1977. https://doi.org/10.1021/ja109226s
Wu CY, Tan Y, Gan ML, Wang YG, Guan Y, Hu XX, Zhou HX, Shang XY, You XF, Yang ZY, Xiao CL (2013a) Identification of elaiophylin derivatives from the marine–derived actinomycete Streptomyces sp. 7–145 using pcr-based screening. J Nat Prod 76:2153–2157. https://doi.org/10.1021/np4006794
Wu ZC, Li SM, Li J, Chen Y, Saurav K, Zhang Q, Zhang H, Zhang W, Zhang W, Zhang S, Zhang C (2013b) Antibacterial and cytotoxic new napyradiomycins from the marine-derived Streptomyces sp. SCSIO 10428. Mar Drugs 11:2113–2125. https://doi.org/10.3390/md11062113
Wu SJ, Fotso S, Li FC, Qin S, Kelter G, Fiebig HH, Laatsch H (2006) N-carboxamido-staurosporine and Selina-4(14),7(11)-diene-8,9-diol, new metabolites from a marine Streptomyces sp. J Antibiot (Tokyo) 59:331–337. https://doi.org/10.1038/ja.2006.46
Wyche TP, Piotrowski JS, Hou Y, Braun DR, Deshpande R, Mcilwain S, Ong IM, Myers CL, Guzei IA, Westler WM, Andes DR, Bugni TS (2014) Forazoline a: marine-derived polyketide with antifungal in vivo efficacy. Angew Chem Int Edit 53:11583–11586. https://doi.org/10.1002/ange.201405990
Wyche TP, Alvarenga RFR, Piotrowski JS, Duster M, Warrack S, Comilescu G, Wolfe TJD, Hou YP, Braun DR, Ellis GA, Simokins SW, Nelson J, Myers CL, Steele JL, Mon H, Safdar N, Markley JL, Rajski SR, Bugni TS (2017) Chemical genomics, structure elucidation, and in vivo studies of the marine-derived anticlostridial ecteinamycin. Acs Chem Biol 12:2287–2295. https://doi.org/10.1021/acschembio.7b00388
Xu LY, Quan XS, Wang C, Wang C, Sheng HF, Zhou GX, Lin BR, Jiang RW, Yao XS (2011) Antimycins A19 and A20, two new antimycins produced by marine actinomycete Streptomyces antibioticus H74–18. J Antibiot (Tokyo) 64:661–665. https://doi.org/10.1038/ja.2011.65
Xu DB, Nepal KK, Chen J, Harmody D, Zhu HN, Mccarthy PJ, Wright AE, Wang GJ (2018) Nocardiopsistins AC: new angucyclines with anti–MRSA activity isolated from a marine sponge-derived Nocardiopsis sp. HB–J378. Synth Syst Biotechnol 3:246–251. https://doi.org/10.1016/j.synbio.2018.10.008
Yamanaka K, Reynolds KA, Kersten RD, Ryan KS, Gonzalez DJ, Nizet V, Dorrestein PC, Moore BS (2014) Direct cloning and refactoring of a silent lipopeptide biosynthetic gene cluster yields the antibiotic taromycin A. Proc Natl Acad Sci 111:1957–1962. https://doi.org/10.1073/pnas.1319584111
Yang XW, Zhang GY, Ying JX, Yang B, Zhou XF, Steinmetz A, Liu YH, Wang N (2013) Isolation, characterization, and bioactivity evaluation of 3-((6-methylpyrazin-2-yl) methyl)–1H–indole, a new alkaloid from a deep–sea–derived actinomycete Serinicoccus profundi sp. nov. Mar Drugs 11:33–39. https://doi.org/10.3390/md11010033
Yang CL, Wang YS, Liu CL, Zeng YJ, Cheng P, Jiao RH, Bao SX, Huang HQ, Tan RX, Ge HM (2017) Strepchazolins A and B: two new alkaloids from a marine Streptomyces chartreusis NA02069. Mar Drugs 15:244. https://doi.org/10.3390/md15080244
Ye X, Anjum K, Song TF, Wang WL, Yu SR, Huang HC, Lian XY, Zhang ZZ (2016) A new curvularin glycoside and its cytotoxic and antibacterial analogues from marine actinomycete Pseudonocardia sp. HS7. Nat Prod Res 30:1156–1161. https://doi.org/10.1080/14786419.2015.1047775
Yi WW, Li Q, Song TF, Chen L, Li XC, Zhang ZZ, Lian XY (2019) Isolation, structure elucidation, and antibacterial evaluation of the metabolites produced by the marine-sourced Streptomyces sp. ZZ820. Tetrahedron 75:1186–1193. https://doi.org/10.1016/j.tet.2019.01.025
Yuan GJ, Lin H, Wang C, Hong K, Liu Y, Li J (2011) 1H and 13C assignments of two new macrocyclic lactones isolated from Streptomyces sp. 211726 and revised assignments of Azalomycins F3a, F4a and F5a. Magn Reson Chem 49:30–37. https://doi.org/10.1002/mrc.2697
Zhang J, Qian Z, Wu X, Ding J, Lu C, Shen Y (2014) Juanlimycins A and B, ansamycin macrodilactams from Streptomyces sp. Org Lett 16:2752–2755. https://doi.org/10.1021/ol501072t
Zhang Q, Mándi Z, Li S, Chen Y, Zhang W, Tian X, Zhang H, Li H, Zhang W, Zhang S, Ju J, Kurtán T, Zhang C (2012) N-N–Coupled indolo–sesquiterpene atropo-diastereomers from a marine-derived actinomycete. Eur J Org Chem 16:2752–2755. https://doi.org/10.1002/ejoc.201200599
Zhang HB, Saurav K, Yu ZQ, Mandi A, Kurtan T, Li J, Tian XP, Zhang QB, Zhang WJ, Zhang CS (2016a) α-Pyrones with diverse hydroxy substitutions from three marine–derived Nocardiopsis Strains. J Nat Prod 79:1610–1618. https://doi.org/10.1021/acs.jnatprod.6b00175
Zhang Y, Adnani N, Braun DR, Ellis GA, Barns KJ, Parkernance S, Guzei IA, Bugni TS (2016b) Micromonohalimanes A and B: Antibacterial halimane-type diterpenoids from a marine Micromonospora species. J Nat Prod 79:2968–2972. https://doi.org/10.1021/acs.jnatprod.6b00555
Zhang B, Wang KB, Wang W, Bi SF, Mei YN, Deng XZ, Jiao RH, Tan RX, Ge HM (2018a) Discovery, biosynthesis, and heterologous production of streptoseomycin, an anti–microaerophilic bacteria macrodilactone. Org Lett 20:2967–2971. https://doi.org/10.1021/acs.orglett.8b01006
Zhang D, Shu CY, Lian XY, Zhang ZZ (2018b) New antibacterial bagremycins F and G from the marine-derived Streptomyces sp. ZZ745. Mar Drugs 16:330. https://doi.org/10.3390/md16090330
Zhang SW, Gui C, Shao MW, Kumar PS, Huang HB, Ju JH (2018c) Antimicrobial tunicamycin derivatives from the deep sea-derived Streptomyces xinghaiensis SCSIO S15077. Nat Prod Res. https://doi.org/10.1080/14786419.2018.1493736
Zhang D, Yi WW, Ge HJ, Zhang ZZ, Wu B (2019a) Bioactive Streptoglutarimides A-J from the Marine-Derived Streptomyces sp. ZZ741. J Nat Prod 82:2800–2808. https://doi.org/10.1021/acs.jnatprod.9b00481
Zhang S, Xie Q, Sun C, Tian XP, Gui C, Win XJ, Zhang H, Ju JH (2019b) Cytotoxic kendomycins containing the carbacylic ansa scaffold from the marine-derived Verrucosispora sp. SCSIO 07399. J Nat Prod 82:3366–3371. https://doi.org/10.1021/acs.jnatprod.9b00654
Zhao C, Zhu T, Zhu W (2013) New marine natural products of microbial origin from 2010 to 2013. Chin J Org Chem 33:1195–1234
Zhou X, Huang H, Chen Y, Tan JH, Song YX, Zou JH, Tian XP, Hua Y, Ju JH (2012) Marthiapeptide A, an anti–infective and cytotoxic polythiazole cyclopeptide from a 60 L scale fermentation of the deep sea-derived Marinactinospora thermotolerans SCSIO 00652. J Nat Prod 75:2251–2255. https://doi.org/10.1021/np300554f
Zhou X, Huang HB, Li J, Song YX, Jiang RW, Liu J, Zhang S, Hua Y, Ju JH (2014) New anti–infective cycloheptadepsipeptide congeners and absolute stereochemistry from the deep sea-derived Streptomyces drozdowiczii SCSIO 10141. Tetrahedron 70:7795–7801. https://doi.org/10.1016/j.tet.2014.02.007
Acknowledgements
This work was financially supported mainly by Seed Grants from University of Hawaii at Hilo (UHH), start-up funding from University of Hawaii Cancer Center and Daniel K. Inouye College of Pharmacy (DKICP), and the Victoria S. and Bradley L. Geist Foundation (15ADVC-74420 and 17CON-86295) (to SC). Funding for this work was also supported by Hawaii IDeA Network for Biomedical Research Excellence III and IV (INBRE-III and INBRE-IV) project: NIGMS Grant 5P20GM103466.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wang, C., Lu, Y. & Cao, S. Antimicrobial compounds from marine actinomycetes. Arch. Pharm. Res. 43, 677–704 (2020). https://doi.org/10.1007/s12272-020-01251-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-020-01251-0